Lending R E, Gall E P, Buchsbaum H W, Foote R A
Arch Intern Med. 1984 Nov;144(11):2259-60.
Sulindac (Clinoril), a nonsteroidal anti-inflammatory agent, has few reported neurologic toxic effects, all of which have been associated with systemic disease. To our knowledge, we describe the first reported case of isolated paresthesia and peripheral neuropathy, without systemic involvement, secondary to sulindac administration. A healthy, 30-year-old man, exposed to sulindac on two separate occasions, had an incapacitating isolated idential sensory neuropathy. The onset and duration of symptoms correlated directly to drug ingestion. This hypersensitivity response cannot be explained pathophysiologically by any mechanism. Repeated exposure and rechallenge of the subject to sulindac was deemed too dangerous, and precludes exact method to establish mechanisms to explain this transient, reproducible, idiosyncratic, adverse drug reaction.
舒林酸(奇诺力)是一种非甾体抗炎药,据报道其神经毒性作用较少,且所有这些作用都与全身性疾病有关。据我们所知,我们描述了首例因服用舒林酸继发的、无全身受累的孤立性感觉异常和周围神经病变的报告病例。一名健康的30岁男性,在两个不同场合接触过舒林酸,出现了致残性的孤立性相同感觉神经病变。症状的发作和持续时间与药物摄入直接相关。这种超敏反应无法用任何病理生理机制来解释。让该受试者再次接触和激发舒林酸被认为过于危险,并且排除了确定解释这种短暂、可重复、特异质药物不良反应机制的精确方法。